Anti-Human CD9 Fab Fragment Antibody Blocks the Extracellular Vesicle-Mediated Increase in Malignancy of Colon Cancer Cells

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung



Intercellular communication between cancer cells themselves or with healthy cells in the tumor microenvironment and/or pre-metastatic sites plays an important role in cancer progression and metastasis. In addition to ligand–receptor signaling complexes, extracellular vesicles (EVs) are emerging as novel mediators of intercellular communication both in tissue homeostasis and in diseases such as cancer. EV-mediated transfer of molecular activities impacting morphological features and cell motility from highly metastatic SW620 cells to non-metastatic SW480 cells is a good in vitro example to illustrate the increased malignancy of colorectal cancer leading to its transformation and aggressive behavior. In an attempt to intercept the intercellular communication promoted by EVs, we recently developed a monovalent Fab fragment antibody directed against human CD9 tetraspanin and showed its effectiveness in blocking the internalization of melanoma cell-derived EVs and the nuclear transfer of their cargo proteins into recipient cells. Here, we employed the SW480/SW620 model to investigate the anti-cancer potential of the anti-CD9 Fab antibody. We first demonstrated that most EVs derived from SW620 cells contain CD9, making them potential targets. We then found that the anti-CD9 Fab antibody, but not the corresponding divalent antibody, prevented internalization of EVs from SW620 cells into SW480 cells, thereby inhibiting their phenotypic transformation, i.e., the change from a mesenchymal-like morphology to a rounded amoeboid-like shape with membrane blebbing, and thus preventing increased cell migration. Intercepting EV-mediated intercellular communication in the tumor niche with an anti-CD9 Fab antibody, combined with direct targeting of cancer cells, could lead to the development of new anti-cancer therapeutic strategies.


PublikationsstatusVeröffentlicht - 10 Aug. 2022

Externe IDs

PubMed 36010551
Scopus 85137126989
Mendeley 6389efbb-0f9b-3801-9460-135586e86d33
ORCID /0000-0001-7687-0983/work/142253733


Ziele für nachhaltige Entwicklung


  • FAB Fragment, CANCER, CD9, Humans, Cell Communication, Tumor Microenvironment, Colonic Neoplasms/pathology, Tetraspanin 29/metabolism, Immunoglobulin Fab Fragments/metabolism, Extracellular Vesicles/metabolism, Fab, colon carcinoma, migration, cancer, cell morphology, extracellular vesicle